<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716794</url>
  </required_header>
  <id_info>
    <org_study_id>HE3235-0201</org_study_id>
    <nct_id>NCT00716794</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of HE3235 in Patients With Prostate Cancer</brief_title>
  <official_title>A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbor Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbor Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to
      patients with advanced prostate cancer who have failed hormone therapy and at least one
      taxane based chemotherapy regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerance of HE3235 when administered orally to prostate cancer patients in 28 day cycles.</measure>
    <time_frame>Treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profiles of HE3235 and major metabolites at different dose levels after 28 days of dosing.</measure>
    <time_frame>Treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess potential activity of HE3235 in prostate cancer patients.</measure>
    <time_frame>Treatment period and post-study follow-up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore circulating tumor cell (CTC) enumeration in response to treatment as a marker evaluating whether an investigational therapy is effective for tumor treatment</measure>
    <time_frame>Treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response.</measure>
    <time_frame>Treament period and post-study follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HE3235</intervention_name>
    <description>HE3235 will be administered orally in 28 day cycles.</description>
    <other_name>Apoptone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patient is male and at least 18 years of age, at the time of screening;

          -  Patient has metastatic disease (any T, any N, M1);

          -  Patient has failed at least 1 taxane regimen; or Patient has symptomatic or
             asymptomatic CRPC and is chemotherapy-naiÌˆve

          -  Patient has histologically or cytologically confirmed adenocarcinoma of the prostate;

          -  Patient has progression of disease despite adequate hormone therapy, demonstrated by
             one of the following:

               -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions,
                  at least 1 week apart.

               -  Evaluable disease progression by modified RECIST (Response Evaluation Criteria in
                  Solid Tumors) criteria;

               -  Progression of metastatic bone disease on bone scan with &gt; 2 new lesions

          -  Patient has ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;

        Main Exclusion Criteria:

          -  Patient has symptomatic parenchymal brain metastases or active epidural disease
             requiring whole-brain irradiation Treated epidural disease is allowed

          -  Patient has active infection;

          -  Patient having a history of clinically significant cardiovascular disease (such as
             CHF), clinically significant hepatic, respiratory or renal abnormalities;

          -  Patient who has any clinically significant abnormalities in laboratory results at
             screening

          -  Patient who has a history of clinically significant neurological or psychiatric
             condition;

        Additional criteria are applicable to expansion cohorts.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight Stickney, MD</last_name>
    <role>Study Director</role>
    <affiliation>Harbor Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nanette Onizuka-Handa/Sr. Vice President, Regulatory Affairs and Quality</name_title>
    <organization>Harbor BioSciences, Inc.</organization>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>HE3235</keyword>
  <keyword>Apoptone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

